

ALTEON INC /DE  
Form 8-K  
June 28, 2007

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 28, 2007**

**ALTEON INC.  
(Exact name of registrant as specified in its charter)**

<b>Delaware</b> <b>(State or other jurisdiction of incorporation)</b>	<b>001-16043</b> <b>(Commission File Number)</b>	<b>13-3304550</b> <b>(IRS Employer Identification No.)</b>
--	---	---

**221 West Grand Avenue  
Montvale, New Jersey 07645  
(Address of principal executive offices and zip code)**

**Registrant's telephone number, including area code: (201) 934-5000**

**Not Applicable**

---

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

- “ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**ITEM 8.01 OTHER EVENTS.**

On June 28, 2007, Alteon Inc. (the “Company”) announced that it has dosed its first patient in a 60-patient Phase 2 clinical trial (Study 201) of ALT-2074, its lead glutathione peroxidase mimetic, in diabetic patients with a variant of haptoglobin that renders them at high risk for cardiovascular complications. This dose escalating study is designed to evaluate ALT-2074’s ability to lower inflammatory cardiovascular biomarkers in patients with an elevated risk for cardiovascular events. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.**

(d) Exhibits.

99.1 Press Release dated June 28, 2007.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ALTEON INC.**

Date: June 28, 2007

By: /s/ Noah Berkowitz, M.D. , Ph.D.

---

Noah Berkowitz, M.D., Ph.D.  
President and Chief Executive Officer

EXHIBIT INDEX

Exhibit Number

Description

99.1

Press Release dated June 28, 2007.

4

---

